Literature DB >> 20634043

Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia.

L C Bresee1, S R Majumdar, S B Patten, J A Johnson.   

Abstract

PURPOSE: To compare the prevalence of cardiovascular risk factors (CV-RF) and disease (CV-D) and health care use in people with and without schizophrenia. SUBJECTS/
MATERIALS AND METHODS: Data from the Canadian Community Health Survey (CCHS), cycle 3.1, were used. Prevalence of CV-RF, CV-D, and health care use were compared in those with and without schizophrenia using logistic regression analysis. Sampling weights and bootstrap variance estimates were used to account for survey design.
RESULTS: A total of 399 (0.3%) people with schizophrenia were identified and compared to 120,044 (97.7%) people without. Individuals with schizophrenia were significantly more likely to be obese (34.8% vs. 15.6%) and report diabetes (11.9% vs. 5.3%). After accounting for sociodemographic variables, schizophrenia was not independently associated with diabetes (adjusted odds ratio [aOR]: 0.86; 0.49-1.51). Individuals with schizophrenia were more likely to be hospitalized (21.9% vs. 8.0%; aOR: 2.37; 95% CI: 1.51-3.74) but no more likely to visit their physician (86.7% vs. 85.7%; aOR: 1.23; 95% CI: 0.65-2.35). DISCUSSION/
CONCLUSION: Our findings suggest that people with schizophrenia access the primary health care system at least as frequently as someone without schizophrenia, and the opportunity for management of modifiable CV-RF exists in this vulnerable population.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20634043     DOI: 10.1016/j.eurpsy.2010.05.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

Review 1.  Serious psychological distress and diabetes: a review of the literature.

Authors:  Leonard E Egede; Clara E Dismuke
Journal:  Curr Psychiatry Rep       Date:  2012-02       Impact factor: 5.285

2.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

3.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

4.  Ethnic differences in primary care management of diabetes and cardiovascular disease in people with serious mental illness.

Authors:  Rohini Mathur; Sally A Hull; Kambiz Boomla; John Robson
Journal:  Br J Gen Pract       Date:  2012-08       Impact factor: 5.386

Review 5.  An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review.

Authors:  Jason C Simeone; Alexandra J Ward; Philip Rotella; Jenna Collins; Ricarda Windisch
Journal:  BMC Psychiatry       Date:  2015-08-12       Impact factor: 3.630

6.  Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia.

Authors:  Cüneyt Unsal; Mustafa Oran; Hande Oktay Tureli; Seref Alpsoy; Sema Yeşilyurt; Mehtap Arslan; Birol Topcu; Osman Karakaya; Erhan Kurt
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-08       Impact factor: 2.570

7.  Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors.

Authors:  Karine Zortea; Viviane C Franco; Lenise P Francesconi; Keila M M Cereser; Maria Inês R Lobato; Paulo S Belmonte-de-Abreu
Journal:  Nutrients       Date:  2016-01-29       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.